Counterfeit medicines in Egypt are a supply-chain problem, a regulatory problem and a packaging problem all at once. When a falsified product reaches a pharmacy shelf, it can pass for a genuine medicine to almost everyone who handles it. That makes packaging the first thing a counterfeiter copies and the first thing a brand owner must be able to defend.
For pharmaceutical manufacturers, brand owners and regulatory teams, the question is how to make genuine packaging harder to imitate and easier to verify, not only how to detect fakes after the fact.
This blog explains the counterfeit landscape in Egypt, how falsified products enter pharmaceutical supply chains, where packaging is vulnerable, and how secure foil and product identification fit into a broader anti-counterfeit strategy.
Counterfeit medicines in Egypt are best addressed through layered protection: secure primary packaging such as hologram and printed foils, serialization and track-and-trace, controlled distribution, and verification tools that pharmacists and patients can actually use.
Understanding the Counterfeit Medicine Landscape in Egypt
Counterfeit or falsified medicines are products that deliberately misrepresent their identity, composition or source. They may contain no active ingredient, the wrong dose, a different ingredient, or harmful contaminants, while carrying the name and appearance of a trusted brand.
The World Health Organization estimates that at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified. This is an estimate for low- and middle-income countries and should not be interpreted as an Egypt-specific statistic. This is a global or regional estimate and should not be interpreted as an Egypt-specific statistic. Egypt, like other markets with complex pharmaceutical supply chains, continues to strengthen systems designed to improve product identification, traceability and regulatory oversight.
Egypt has also strengthened pharmaceutical traceability through the Egyptian Track & Trace System (EPTTS), overseen by the Egyptian Drug Authority (EDA). Under the Phase 1 technical requirements published in 2026, serialization is mandatory at the secondary-packaging level, with EPTTS requiring a Data Matrix ECC 200 containing key product information such as GTIN, serial number, expiry date and batch/lot. Manufacturers and exporters should verify the latest EDA requirements before finalizing packaging artwork, serialization workflows or security features.
Common risk categories in markets like Egypt include:
- High-demand chronic and lifestyle medicines
- Products affected by shortages or price gaps
- Medicines sold through informal or unverified channels
- Brands with strong reputations and visible packaging
How Counterfeit Products Enter Pharmaceutical Supply Chains
Counterfeit products rarely arrive through one obvious door. They typically enter wherever visibility is lowest.
Common entry points include:
- Unauthorized or unlicensed distributors and intermediaries
- Parallel trade and repackaging outside controlled channels
- Diversion and re-entry of genuine, expired or returned stock
- Online sales and informal retail outlets
- Cross-border movement through less-monitored routes
The longer and more fragmented the supply chain, the more handover points exist where a falsified pack can be swapped in. This is why supply-chain transparency and packaging security have to work together.
Packaging Vulnerabilities That Can Enable Imitation
Counterfeiters are not copying the medicine first. They are copying what people see and trust: the carton, the blister card and the printed foil. Packaging that is easy to reproduce is easy to fake.
Typical packaging vulnerabilities include:
- Standard printed foil with no unique security feature
- Simple printing that can be replicated with commercial equipment
- Cartons and leaflets that can be reproduced more easily than primary packaging
- Absence of covert or machine-readable identifiers
- Unclear visual cues that pharmacists and patients cannot easily check
The closer a security feature sits to the medicine itself, the harder it is to remove, reuse or convincingly imitate.
This is why primary packaging, especially the blister foil that directly seals each dose, is an important place to add protection. A carton can be replaced. A foil that carries integrated security features is far harder to duplicate.
Why Authentication and Product Identification Matter
Protection only works if someone can check it. Authentication turns packaging from a passive container into an active line of defense.
Effective authentication generally combines several layers:
- Overt features: visible to the naked eye, such as holograms and distinctive foil patterns, for quick checks by pharmacists and patients
- Covert features: hidden marks or inks that trained inspectors or tools can verify
- Digital identifiers: serialized identifiers such as 2D Data Matrix codes, which can connect individual packs with traceability systems and product information.
- Batch-level traceability: consistent batch, manufacturing and expiry information that can be cross-checked
A pack that can be identified, traced and verified gives regulators, distributors and patients something concrete to rely on, and gives brand owners evidence when a suspect product is found.
Regulatory and Supply-Chain Considerations
Packaging decisions for the Egyptian market should be made with regulators and the supply chain in mind, not just the artwork team.
Key considerations for manufacturers and exporters include:
- Alignment with current EDA registration, labeling and EPTTS serialization requirements, including applicable secondary-packaging identification requirements
- Compatibility of security features with high-speed blister packaging lines
- Consistent artwork control, including Arabic and multilingual text requirements
- Documented supplier qualification and quality agreements for packaging materials
- Coordination between packaging, regulatory, QA/QC and supply-chain teams
Security features must also be practical. A feature that disrupts sealing performance, print registration or line speed will not survive production, however impressive it looks.
The Role of Secure Packaging in a Broader Anti-Counterfeit Strategy
No single feature stops counterfeiting. Secure packaging is one layer in a wider strategy that also includes serialization, distributor control, market surveillance, staff training and cooperation with authorities.
Where packaging contributes most:
- Deterrence: advanced foil features raise the cost and difficulty of copying
- Detection: overt and covert features give inspectors and pharmacists a fast way to spot suspect products
- Protection of integrity: strong, consistent foil structures keep the medicine protected until the moment of use
- Brand confidence: visible security reassures healthcare professionals and patients
The most effective approach layers these features so that a counterfeiter would have to defeat several at once.
How Sanwariya Packaging Supports Anti-Counterfeit Strategies
Sanwariya Packaging is a manufacturer and exporter of pharmaceutical aluminum foils, both unprinted and printed, built for reliable barrier performance, consistent sealing and stable print quality.
For brand owners concerned about imitation, relevant options include:
- Hologram Security Foils that add visible, hard-to-replicate authentication directly to the primary pack
- Blister Foils with precise printing to keep identification details clear and consistent
- Alu Alu Cold Forming Foils for high-barrier protection of sensitive formulations
- Strip/Laminated Foils and Multi-Layer Foils for varied packaging formats
Through controlled manufacturing and strict quality processes, Sanwariya works with pharmaceutical companies to develop foil solutions that combine protection, printability and security for demanding export markets.
Ready to strengthen your packaging against counterfeiting? Get in touch with our team or request a quote.
